Measles Vaccination: New Strategies and Formulations

Rory D de Vries; Koert J Stittelaar; Albert DME Osterhaus; Rik L de Swart


Expert Rev Vaccines. 2008;7(8):1215-1223. 

In This Article

Five-year View

In the next 5 years, the Measles Initiative will extend its activities from sub-Saharan Africa to South-East Asia, which will contribute to further reduction of measles mortality. Measles vaccines delivered by the aerosol route may be licensed for human use, which will provide a new tool to strengthen measles control programs and facilitate supplementary immunization activities. Assuming that global eradication of polio will be successful, the WHO will have to make a decision regarding whether measles will be the next target for eradication.[99] Despite progress in the development of new-generation measles vaccines, these will not become available for human use within the next 5 years. However, if the performance of vectored or DNA vaccines could be improved, these might be pushed into clinical trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: